merck - Search News

News

Merck KGaA, SpringWorks

Germany's Merck says in late-stage discussions to buy SpringWorks for $3.5 billion

Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 billion, a deal that could give it access to a recently approved rare disease drug and expand its portfolio of experimental cancer treatments.

GlobalData on MSN · 18h

Merck KGaA nears $3.5bn deal for SpringWorks

Merck KGaA has confirmed that it is in late-stage discussions with SpringWorks, valuing the deal at a price of around $47 per share.

BioSpace · 23h

SpringWorks Surges on Potential $3.5B Merck KGaA Buyout

The transaction, which sources say could be agreed upon as soon as Monday, would price SpringWorks at $47 per share, totaling approximately $3.5 billion for the acquisition.

Merck lowers profit Outlook

Bloomberg on MSN · 1d

Merck Expects $200 Million Hit From Current US Tariffs

Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid a roiling trade war between the US and China.

CNBC on MSN · 1d

Merck lowers profit outlook, partly due to $200 million expected tariff hit

Merck said the expected tariff charge primarily reflects levies between the U.S. and China, but does not account for Trump’s planned pharmaceutical tariffs.

Crain's New York Business · 1d

Merck expects $200M tariff hit amid Gardasil fallout

The company’s stock fell as much as 2.8% after markets opened in New York Thursday. For the first quarter, Merck’s results beat estimates. First quarter sales were $15.5 billion, above the $15.3 billion analysts had predicted. Adjusted earnings of $2.22 per share outpaced expectations of $2.13 a share.

Halozyme sues Merck; FDA blames cuts for Vanda delay

Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...

pharmaphorum1d

Merck puts a price on its SpringWorks takeover bid

So far, SpringWorks – which was spun out of Pfizer in 2017 and has recently received FDA approval for a second therapy for a ...

16h

Merck Stays Confident On M&A Despite Market Uncertainty: Analyst

Merck projects $200 million in tariff costs, boosts U.S. manufacturing plans, and continues M&A efforts amid external pressures and shifting market dynamics.

Fierce Pharma1d

Merck ‘willing to work’ with Trump administration on price gap between US, international medicines

With potential tariffs and other drug pricing policies on the horizon, the industry is navigating uncertain waters. | The ...

STAT19h

Akeso wins Chinese approval for cancer drug positioned to rival Merck’s Keytruda

Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data ...